Introduction {#S1}
============

Alzheimer's disease is a neurodegenerative disease that is the major cause of dementia worldwide ([@B7]). The AD brain is characterized by the distribution of amyloid plaques and neurofibrillary tangles, which are composed of Aβ and hyperphosphorylated tau proteins, respectively ([@B157]; [@B153]). The generation of Aβ from amyloid precursor protein (APP) is a central theme in the field of AD. APP is a single transmembrane protein with a large extracellular domain that is generated in large quantities and efficiently metabolized. APP can be processed via non-amyloidogenic or amyloidogenic generation of Aβ ([@B33]). Aβ mainly exists in two forms, Aβ~40~ and a more hydrophobic Aβ~42~, which consist of 40 and 42 amino acids, respectively ([@B90]). The Aβ monomer is intrinsically disordered, and present as a dynamic conformational structure ([@B27]), which allows the monomer binds to numerous substrate with a high binding affinity. The monomers of Aβ aggregate into oligomers, fibrils, and plaques, when a critical concentration of amyloid is reached due to dysfunctional homeostasis ([@B76]). The soluble Aβ oligomer is recognized as the major neurotoxic species, and exists in an equilibrium with fibrils ([@B167]). And the toxicity of Aβ oligomers is inversely correlated with their oligomer size ([@B135]). Aβ is directly neurotoxic and induces a series of cellular responses; for example, it can induce excitotoxic signaling by increasing glutamate release ([@B17]), and alter Ca^2+^ homeostasis and synaptic functions in neurons, astrocytes, and microglia ([@B118]). Aβ located on the mitochondria generates ROS, thus increasing oxidative stress and disrupting oxidative phosphorylation ([@B24]). Aβ also activates protein kinase to phosphorylate tau protein, resulting in the formation of neurofibrillary tangles ([@B56]). The toxicity of both Aβ and hyperphosphorylated tau proteins are dependent on one another; an absence of tau protein reduces Aβ-induced memory impairment, while increased Aβ levels promote tau pathology ([@B112]; [@B125]).

The amyloid cascade hypothesis was proposed in 1992, and depicts Aβ as the causative factor in AD development ([@B53]). This hypothesis has genetic-based support, because mutations in genes related to Aβ formation (*APP* and *PSEN*) and clearance (*APOE4*) induce early-onset AD ([@B129]; [@B75]; [@B139]). However, this hypothesis is challenged by two facts, although there are also counterarguments that have been proposed from other scientific findings. First, amyloid imaging reveals that Aβ deposition also occurs in healthy aging subjects, suggesting that Aβ deposition could be a normal phenomenon of aging ([@B38]). However, [@B40] suggested that Aβ oligomer levels, which are the neurotoxic form of Aβ deposition, are higher in AD brains compared with healthy subjects. Second, the degree of dementia does not correlate well with amyloid plaque formation in AD ([@B104]). In fact, Aβ oligomers may exert their neurotoxic effects much earlier, before the formation of amyloid plaques ([@B18]). Also, the drug development for the treatment of AD has been guided by the amyloid cascade hypothesis for the pass two decade, although most anti-Aβ drugs fail in clinical trials and no novel drugs have been brought to market since 2003 ([@B36]). For example, Solanezumab (currently in a phase 3 trial) recognizes Aβ at the 13 to 28 amino acid position and lowers amyloid levels, but does not show beneficial effects in subjects with mild AD ([@B60]). Verubecestat (currently in a phase 3 trial), a β-secretase inhibitor, reduces Aβ levels in a dose-dependent manner ([@B72]). However, a recent clinical trial ([@B39]) indicated that verubecestat does not have clinical effects in AD subjects. The failure of development of anti-Aβ drugs does not discredit amyloid as the central theme for AD treatment, because the sporadic AD is caused by the changes of genes which potentiate the neurotoxicity of Aβ in the brain over years, rather than solely Aβ overproduction. Indeed, the cerebral Aβ~42~ kinetics were modified by Aβ accumulation ([@B120]), resulting in the disease preventative treatment required at least 95% lowering Aβ~42~ production if the treatment was started after Aβ accumulation ([@B126]). This suggests that the development of anti-Aβ drugs should not be solely dependent on inhibition of Aβ~42~ production. However, the incomplete knowledge of AD pathogenic factors may hindered the investigation of AD ([@B134]), not just Aβ production, but also the Aβ-relevant receptors and their corresponding downstream signaling cascades.

Alzheimer's disease is a complex disorder, expressed as a malfunction of defects in multiple genes. The discovery of AD pathogenic factors can be revealed by transcriptome profiling approach \[i.e., DNA microarray and RNA-Seq ([@B144])\] to identify DEGs in AD subjects compared with healthy subjects. DEGs are genes that are potentially associated with disease pathology. [Table 1](#T1){ref-type="table"} shows the publications using transcriptomic data and bioinformatics tools for identifying AD pathogenic factors. [@B122] identified common DEGs from microarray datasets across six different brain regions. All datasets were integrated using the Colored (α, β)-κ Feature set approach ([@B121]), and a few common DEGs were identified across the brain regions, revealing an AD-specific signature. [@B71] used the BC3Net10 algorithm to infer AD gene regulatory networks. This network was generated by the integration of literature-based knowledge and data-driven analysis. Inferences did not solely depend on the network topology, but also integrated information about DEGs and AD-related genes, after systematic searching from databases. However, the DEGs obtained from different transcriptomic studies of AD are sometimes conflicting because of many factors, such as the use of different experimental designs or statistical methods between studies. The integration of these studies based on meta-analysis therefore resolves inconclusive results and obtains a generalization ([@B51]). The results of meta-analysis are presented as logORs based on the number of dysregulation events in both disease and control samples. The effect sizes are integrated to assess the overall effect size based on either fixed- or random-effect models. Meta-analysis has been applied in genomic analyses to assess the effectiveness of a particular gene in AD. [@B97] conducted a meta-analysis using the R package *RobustRankAggreg* to identify statistically significant DEGs in AD across six microarray datasets. The DEGs were further corroborated with three RNA-Seq datasets and input for biological enrichment analysis to reveal the miRNAs that regulate the DEGs. Furthermore, [@B156] conducted a meta-analysis using the R package *RankProd* to explore the molecular mechanisms of AD across seven microarray datasets. They found 37 DEGs commonly shared by six brain regions, and most of these DEGs were downregulated. The significantly enriched pathways of DEGs were associated with mitochondrial oxidative phosphorylation and synaptic vesicle function. However, both studies only focused on a single microarray platform (Affymetrix), and the meta-analysis of DEGs did not include the gene expression profiles from RNA-Seq. For the study by Moradifard et al., the DEGs from RNA-Seq were only used to validate the results of microarray datasets; that is, the DEGs common to both the RNA-Seq and microarray datasets, in the same dysregulated direction. It seems that the results of currently available meta-analyses of DEGS for identifying AD pathogenic genes are limited by the use of microarray platforms and the inability to integrate results from both microarray and RNA-Seq.

###### 

The published transcriptomic data and bioinformatics tools for identifying AD pathogenic factors.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Title                                                                                                                                                                                                                  Authors (publication year)   Database                                                                                             Bioinformatic tools                                                                                                  Pathogenic factors
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Integrated Identification of Key Genes and Pathways in Alzheimer's Disease via Comprehensive Bioinformatical Analyses ([@B166])                                                                                        [@B166]                      GEO, KEGG, Reactome, STRING, Wikipathway                                                             Platform: Morpheus, RBPDB, UCSC;\                                                                                    *BDNF*, *CACNA1A*, *CALB*, *CD44*, *CDC42*, *OXT*, *PDYN*, *TAC1*, *TH*, *VEGFA*
                                                                                                                                                                                                                                                                                                                                                           Software: Cytoscape, ClueGO, Gluepedia, Graphpad Prism, MCODE                                                        

  Systematic Analysis and Biomarker Study for Alzheimer's Disease ([@B84])                                                                                                                                               [@B84]                       GEO, International Genomics of Alzheimer's Project                                                   R package: *affy*, *glmnet*, *limma*, *MASS*, *PRROC*, *ROCR*;\                                                      *NDUFA1*, *MRPL51*, *RPL36AL*
                                                                                                                                                                                                                                                                                                                                                           Software: Ingenuity Pathway Analysis, MAGMA                                                                          

  Network-based approach to identify molecular signatures and therapeutic agents in Alzheimer's Disease ([@B123])                                                                                                        [@B123]                      CMap, GEO, JASPAR, miRTarBase, STRING, TarBase                                                       Platform: DAVID, GEO2R;\                                                                                             *AR*, *CREBBP*, *E2F1*, *FOXC1*, *FOXL1*, *GATA2*, *JUN*, *NFIC*, *PPARG*, *RAC1*, *RPL12*, *RPL15*, *RPS11*, *RPS6*, *SMAD3*, *SRF*, *UBA52*, *UBC*, *USF2*, *YY1*
                                                                                                                                                                                                                                                                                                                                                           Software: CytoHubba, Cytoscape, MCODE                                                                                

  Alzheimer's Disease Master Regulators Analysis: Search for Potential Molecular Targets and Drug Repositioning Candidates ([@B152])                                                                                     [@B152]                      CMap, GEO                                                                                            Algorithm: Algorithm for the Reconstruction of Accurate Cellular Networks, two-tail gene set enrichment analysis;\   *ATF2*, *CNOT7*, *CSRNP2*, *PARK2*, *SLC30A9*, *TSC22D1*
                                                                                                                                                                                                                                                                                                                                                           R package: *ggplot2*, *RedeR*, *RTN*                                                                                 

  Condition-specific Gene Co-expression Network Mining Identifies Key Pathways and Regulators in the Brain Tissue of Alzheimer's Disease Patients ([@B164])                                                              [@B164]                      Allen Brain Institute, GEO                                                                           Algorithm: Local maximized Quasi-Clique Merger;\                                                                     *FOS, JUN, MEF2A, MIB2, PCBP1, SMARCA2, SP1, STAT1, TEAD4, ZFHX3, ZNF281*
                                                                                                                                                                                                                                                                                                                                                           Platform: REViGO;\                                                                                                   
                                                                                                                                                                                                                                                                                                                                                           R package: *Affy*, *Enrichr*, *lmQCM*                                                                                

  Analytical Strategy to Prioritize Alzheimer's Disease Candidate Genes in Gene Regulatory Networks Using Public Expression Data ([@B71])                                                                                [@B71]                       ArrayExpress, CPDB, ENSEMBL, GEO, GWAScatalog, GWASCentral, GWASdb, KEGG, NeuroTransDB, RegulomeDB   Algorithm: BC3Net10;\                                                                                                *AP2A2, ARAP3, ATP2A3, ATP2B4, HLA-C, HLA-F, ITPR2, RAB11FIP4, STX2*
                                                                                                                                                                                                                                                                                                                                                           R package: *affy*, *arrayQualityMetrics*, *bc3net*, *limma*;\                                                        
                                                                                                                                                                                                                                                                                                                                                           Platform: HaploReg, SCAIView                                                                                         

  The Bioinformatic Analysis of the Dysregulated Genes and MicroRNAs in Entorhinal Cortex, Hippocampus, and Blood for Alzheimer's Disease ([@B116])                                                                      [@B116]                      CMap, GEO, KEGG                                                                                      R package: *affy*, *edgeR*, *limma*, *WGCNA*;\                                                                       *CTSD*, *VCAM1*
                                                                                                                                                                                                                                                                                                                                                           Platform: DAVID;\                                                                                                    
                                                                                                                                                                                                                                                                                                                                                           Software: CytoHubba, Cytoscape, GSEA                                                                                 

  A Systematic Integrated Analysis of Brain Expression Profiles Reveals *YAP1* and Other Prioritized Hub Genes as Important Upstream Regulators in Alzheimer's Disease ([@B165])                                         [@B165]                      GEO                                                                                                  R package: *in silico Merging*, *limma*, *WGCNA*                                                                     *YAP1*

  Network Topology Analysis of Post-Mortem Brain Microarrays Identifies More Alzheimer's Related Genes and MicroRNAs and Points to Novel Routes for Fighting with the Disease ([@B26])                                   [@B26]                       ArrayExpress, GEO, OMIN, ResNet                                                                      Algorithm: Robust Multiarray Average approach, empirical Bayes method;\                                              *CD4*, *DCN*, *IL8*
                                                                                                                                                                                                                                                                                                                                                           Platform: DAVID;\                                                                                                    
                                                                                                                                                                                                                                                                                                                                                           Software: Pajek, Pathway Studio                                                                                      

  A Systematic Investigation into Aging Related Genes in Brain and Their Relationship with Alzheimer's Disease ([@B94])                                                                                                  [@B94]                       Biocarta, DisGeNet, GEO, GenAge, GenMapP, MetaBase                                                   Algorithm: Condition-specific target prediction;\                                                                    *ESR1*, *SOX2*, *SP1*
                                                                                                                                                                                                                                                                                                                                                           Platform: DAVID, oPOSSUM;\                                                                                           
                                                                                                                                                                                                                                                                                                                                                           R package: *WGCNA*;\                                                                                                 
                                                                                                                                                                                                                                                                                                                                                           Software: Ingenuity Pathway Analysis                                                                                 

  Identification of Differentially Expressed Genes through Integrated Study of Alzheimer's Disease Affected Brain Regions ([@B122])                                                                                      [@B122]                      GEO                                                                                                  Algorithm: (α,β)-k Feature Set approach, Minimum Description Length Principle;\                                      *FGF*, *GPHN*, *INFAR2*, *LARGE*, *PSMB2*, *PSMD14*, *PTMA*, *RAB2A*, *RPL15*, *RWDD2A*, *SEMA4C*, *WNK1*
                                                                                                                                                                                                                                                                                                                                                           R package: *GeneMeta*, *RankProd*;\                                                                                  
                                                                                                                                                                                                                                                                                                                                                           Software: Expression Analysis Systematic Explorer                                                                    

  Meta-Analysis of Transcriptome Data Related to Hippocampus Biopsies and iPSC-Derived Neuronal Cells from Alzheimer's Disease Patients Reveals an Association with FOXA1 and FOXA2 Gene Regulatory Networks ([@B162])   [@B162]                      GEO, KEGG                                                                                            Platform: oPOSSUM;\                                                                                                  *FOXA1*, *FOXA2*
                                                                                                                                                                                                                                                                                                                                                           R package: *affy*, *Gostats*, *lumi*, *oligo*                                                                        

  A Computational Framework for the Prioritization of Disease-gene Candidates ([@B20])                                                                                                                                   [@B20]                       BIND, BioGPS, BioGRID, DIP, GEO, HPRD, InACT, MINT, PDB                                              Algorithm: Average of Pearson correlation coefficients;\                                                             *CARD9*, *FHL3*, *KRT38*, *LZTS2*, *MID2*, *MTUS2*, *REL*, *TFCP2*, *TRAF1*
                                                                                                                                                                                                                                                                                                                                                           Platform: hORFeome;\                                                                                                 
                                                                                                                                                                                                                                                                                                                                                           R package: *GOSemSim*;\                                                                                              
                                                                                                                                                                                                                                                                                                                                                           Software: Cytoscape, Significance Analysis of Microarrays                                                            

  Identification of Unstable Network Modules Reveals Disease Modules Associated with the Progression of Alzheimer's Disease ([@B73])                                                                                     [@B73]                       BioGRID, GEO                                                                                         Algorithm: Infomap algorithm, MAS algorithm                                                                          *UCHL5*
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

R packages and genes are in italic font.

This study aimed to identify potential pathogenic factors based on the meta-analysis of transcriptomic data from different brain regions in AD. The meta-analysis was conducted according to PRISMA guidelines ([@B96]), including those for dataset search, dataset selection, and statistical analysis. The raw transcriptomic data were retrieved from databases after a systematic search and were analyzed using a consistent workflow, from quality control and normalization to DEG determination. A statistical meta-analysis was performed when more than one study reported the same DEG. The DEGs that remained statistically significant after *P*-value adjustment were collected to perform a biological enrichment analysis and subgroup analysis, and to construct a PPIN. The network information and AD seed genes, which were obtained from the GWAS Catalog ([@B158]), were collected for the DIseAse Module Detection (DIAMoND) algorithm ([@B49]) to examine the significance of the connectivity patterns among network components. This algorithm identified an AD-specific module from the network, and the nodes within the module with a high degree were treated as potential pathogenic factors. The overall study design is illustrated in [Figure 1](#F1){ref-type="fig"}.

![The overall study design.](fnins-14-00209-g001){#F1}

Materials and Methods {#S2}
=====================

Database Search and Dataset Selection {#S2.SS1}
-------------------------------------

The datasets were collected from GEO^[1](#footnote1){ref-type="fn"}^ ([@B8]) and ArrayExpress^[2](#footnote2){ref-type="fn"}^ ([@B77]) from their respective inception dates until January 6, 2019. The search strategy is shown in [Supplementary File S1](#SF1){ref-type="supplementary-material"}.

Raw DNA microarray and RNA-Seq data reporting the transcriptomes of brain regions from AD and healthy subjects were included. The datasets were excluded if they were (1) not case--control studies; (2) focused on other neurodegenerative diseases; (3) demonstrated treatment effects on AD; or (4) used cell-line or artificial AD models. Sample details were collected if they were provided. If the datasets contained several comparisons, DEGs were determined from each comparison independently.

Data Processing {#S2.SS2}
---------------

Each microarray dataset was processed consistently and independently using R packages from Bioconductor. Each dataset was processed through background correction, quantile normalization, and log~2~-transformation of the averaged expression value of duplicate probes, using the *affy* ([@B48]), *oligo* ([@B23]), or *limma* ([@B124]) package. For each dataset, the quality of each array was assessed using the *arrayQualityMetrics* ([@B69]) package. The array was omitted from the subsequent analysis if it was detected as an outliner in any of the three metrics provided by the package. The gene expression ratios between AD and healthy subjects were determined for each dataset using the *limma* package. Genes with an adjusted *P*-value (by FDR) of less than 0.05 were considered to be statistically significant DEGs. The DEGs were annotated using the gene annotation table provided by GEO and ArrayExpress. The probes with missing gene symbols were removed. When multiple probes were annotated with the same gene symbol on the same array, the probe with the highest expression value was kept.

The raw sequence data were converted to FASTQ format using the SRA Toolkit (version 2.9.2) ([@B81]). Quality control on FASTQ was conducted using FastQC (version 0.11.8) ([@B3]): (1) sequences with less than 80% of bases with at least quality of 25 were filtered; and (2) the bases with quality less than 25 were trimmed. The cleaner FASTQ files were aligned to the *Homo.sapiens* reference genome, GRCh38.94 (downloaded from Ensemble), using TopHat (version 2.1.1) ([@B74]). The aligned sequences were sorted based on the aligned position to the reference genome using SAMtools (version 1.9) ([@B82]). After sorting, the count-based gene expression was obtained using HTSeq (version 0.8.0) ([@B2]), and the reads with alignment scores less than 10 were omitted. Differential expression was performed using the *edgeR* ([@B127]) package for R software. RNA-Seq datasets were processed on a Linux-based HP ProLiant DL580 Gen8 workstation \[Inter^®^ Xeon^®^ E7-4820 CPU v2 @ 2.00 GHz; 4 processors with 32 total cores enabled; 128 GB RAM\].

Meta-Analysis, Biological Enrichment Analysis, and Subgroup Analysis {#S2.SS3}
--------------------------------------------------------------------

The list of DEGs and their dysregulation states (i.e., upregulated or downregulated) from each study were processed using the *meta* for [@B34] package for R software. The meta-analysis was conducted under a random-effects model, and their outcomes were logORs with *P*-values. For each gene in the i-th study, the effect (θ*~i~*) based on the numbers of dysregulation events in both AD and control samples was first calculated, then the overall effect was computed according to formula $\frac{\sum{Wi\theta i}}{\sum{Wi}}$, where w~i~ is the weight and is equal to 1/v~i~, where v~i~ is the sample variance. The genes with logORs above or below 0 were considered upregulated or downregulated, respectively. The *P*-values were adjusted by FDR, and DEGs with adjusted *P*-values less than 0.05 were regarded as statistically significant. After meta-analysis, the statistically significant DEGs were used to perform a biological enrichment analysis. The enrichment analysis was conducted by the hypergeometric test using the *clusterProfiler* ([@B171]) package for R software, based on the KEGG^[3](#footnote3){ref-type="fn"}^ ([@B67]). The statistically significant DEGs after meta-analysis were collected as input for the enrichment analysis to identify biological pathways among them. The pathways with FDR-adjusted *P*-values less than 0.05 were considered statistically significant.

The DEGs were split into different subgroups based on which brain regions they were from, to compare expression profiles among brain regions. According to [@B128], brain regions can be hierarchically clustered into three major branches based on cytological differences. The first branch includes the cerebellum. The second branch is sub-categorized into three sub-branches; the first sub-branch includes the putamen and nucleus accumbens, the second sub-branch includes the amygdala and hippocampus, and the third sub-branch includes the cerebral neocortex. The third branch includes the thalamus, brain stem, and spinal cord. Biological enrichment analysis was also conducted in each subgroup.

Protein--Protein Interaction Network and Potential Pathogenic Factors {#S2.SS4}
---------------------------------------------------------------------

After meta-analysis, statistically significant DEGs were used to construct a PPIN based on the data from STRING (version 11^[4](#footnote4){ref-type="fn"}^ ; [@B145]). Only interactions with the highest confidence (0.9) were kept. The PPIN was visualized using Cytoscape ([@B136]). Disease-associated genes are not topologically interacted into a dense network module because disease can be the consequence of perturbation in many functional units. AD seed genes were retrieved from the GWAS Catalog ([@B158])^[5](#footnote5){ref-type="fn"}^ using the key word "AD" and the following selection criteria: a significance *p*-Value cutoff of no more than 1^∗^10^--8^. Genes with official gene symbols were kept as AD seed genes. The PPIN information (e.g., edge list in the co-expression network) and AD seed genes were put into the DIAMOnD algorithm ([@B49]) to evaluate the significance of the connections that each node had with the seed genes in the biological network. In each iteration until the stopping condition was satisfied, the node with the lowest connectivity *P*-value was treated as the most significantly connected node for output. The nodes within the module that had a high degree (\>95th percentile) were treated as potential pathogenic factors.

Risk of Bias {#S2.SS5}
------------

All studies were collected according to the publication information of datasets. If there was more than one publication for one dataset, the publication with the earlier publication year was selected. The risk of bias for the included studies was evaluated according to MIAME (Minimum information about a microarray experiment) ([@B16]) and MINSEQE (Minimum information about a high-throughput nucleotide sequencing experiment^[6](#footnote6){ref-type="fn"}^, proposed by FGED Society in 2012) guidelines by two authors (SY and HZ), independently. Disagreements between the authors were resolved by discussion with the third author (SWL). The MIAME and MINSEQE guidelines are designated to report the quality of DNA microarray and RNA-Seq studies, respectively. And the quality of transcriptomic parts of included studies was assessed, including raw data collection, result presentation, sample annotation, experimental design, array annotation, and data processing pipeline. Items with low risk were counted +1, suggesting high reproducibility; items with unclear risk were counted 0, suggesting ambiguous reproducibility; and items with high risk were counted --1, suggesting low reproducibility.

Results {#S3}
=======

Included Datasets {#S3.SS1}
-----------------

The selection process of the datasets is shown in [Figure 2](#F2){ref-type="fig"}. A total of 225 datasets were initially identified from GEO and ArrayExpress. After removing duplicated datasets and datasets that met the exclusion criteria, 25 datasets (21 for microarray and 4 for RNA-Seq) met the eligibility criteria. The dataset characteristics are shown in [Table 2](#T2){ref-type="table"}. Among the included datasets, the hippocampus (*n* = 8) was the most extensively studied brain region, followed by the entorhinal cortex and prefrontal cortex (*n* = 3).

###### 

The characteristics of included datasets.

  Types            Dataset_ID    Brain tissue                                                                                                                                                                                                                                                                                                                                                                                    Disease stage               Platform                                                                                                            Number of samples   Number of samples omitted
  ---------------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------- ---------------------------
  DNA microarray   E-MEXP-2280   Medial temporal lobe                                                                                                                                                                                                                                                                                                                                                                            Braak stage VI              Affymetrix Human Genome U133 Plus 2.0 Array                                                                         12                  0
                   GSE110226     Choroid plexus                                                                                                                                                                                                                                                                                                                                                                                  Braak stage III to VI       Rosetta/Merck Human RSTA Custom Affymetrix 2.0 microarray                                                           13                  3
                   GSE12685      Frontal cortex                                                                                                                                                                                                                                                                                                                                                                                  MMSE 21 to 27               Affymetrix Human Genome U133A Array                                                                                 14                  3
                   GSE1297       Hippocampus                                                                                                                                                                                                                                                                                                                                                                                     Braak stage at III to VI    Affymetrix Human Genome U133A Array                                                                                 31                  3
                   GSE16759      Parietal lobe cortex                                                                                                                                                                                                                                                                                                                                                                            Braak stage at V to VI      Affymetrix Human Genome U133 Plus 2.0 Array                                                                         8                   1
                   GSE26927      Entorhinal cortex                                                                                                                                                                                                                                                                                                                                                                               --                          Illumina humanRef-8 v2.0 expression beadchip                                                                        18                  4
                   GSE28146      Hippocampus                                                                                                                                                                                                                                                                                                                                                                                     Braak stage at V to VI      Affymetrix Human Genome U133 Plus 2.0 Array                                                                         30                  1
                   GSE29378      Hippocampus                                                                                                                                                                                                                                                                                                                                                                                     Braak stage at V to VI      Illumina HumanHT-12 V3.0 expression beadchip                                                                        63                  2
                   GSE32645      Cortex                                                                                                                                                                                                                                                                                                                                                                                          Braak stage VI              Agilent-014850 Whole Human Genome Microarray 4 × 44K G4112F                                                         6                   0
                   GSE33000      Prefrontal cortex                                                                                                                                                                                                                                                                                                                                                                               --                          Rosetta/Merck Human 44k 1.1 microarray                                                                              467                 30
                   GSE36980      Frontal cortex, hippocampus, temporal cortex                                                                                                                                                                                                                                                                                                                                                    Braak stage at V to VI      Affymetrix Human Gene 1.0 ST Array \[transcript (gene) version\]                                                    79                  8
                   GSE37263      Neocortex                                                                                                                                                                                                                                                                                                                                                                                       Braak stage at III to VI    Affymetrix Human Exon 1.0 ST Array \[transcript (gene) version\]                                                    16                  1
                   GSE39420      Posterior cingulate                                                                                                                                                                                                                                                                                                                                                                             Braak stage at V to VI      Affymetrix Human Gene 1.1 ST Array \[transcript (gene) version\]                                                    21                  0
                   GSE44768      Cerebellum                                                                                                                                                                                                                                                                                                                                                                                      --                          Rosetta/Merck Human 44k 1.1 microarray                                                                              230                 10
                   GSE44770      Prefrontal cortex                                                                                                                                                                                                                                                                                                                                                                               --                          Rosetta/Merck Human 44k 1.1 microarray                                                                              230                 28
                   GSE44771      Visual cortex                                                                                                                                                                                                                                                                                                                                                                                   --                          Rosetta/Merck Human 44k 1.1 microarray                                                                              230                 22
                   GSE48350      Entorhinal cortex, hippocampus, post-central gyrus, superior frontal gyrus                                                                                                                                                                                                                                                                                                                      Braak stage at II to VI     Affymetrix Human Genome U133 Plus 2.0 Array                                                                         253                 16
                   GSE5281       Entorhinal cortex, hippocampus, medial temporal gyrus, posterior cingulate, primary visual cortex, superior frontal gyrus                                                                                                                                                                                                                                                                       --                          Affymetrix Human Genome U133 Plus 2.0 Array                                                                         161                 11
                   GSE61196      Choroid plexus                                                                                                                                                                                                                                                                                                                                                                                  Braak stage at III and VI   Agilent-014850 Whole Human Genome Microarray 4 × 44K G4112F                                                         21                  1
                   GSE84422      Amygdala, anterior cingulate, caudate nucleus, dorsolateral prefrontal cortex, frontal pole, hippocampus, inferior frontal gyrus, inferior temporal gyrus, middle temporal gyrus, nucleus accumbens, occipital visual cortex, parahippocampal gyrus, posterior cingulate cortex, precentral gyrus, prefrontal cortex, putamen, temporal polesuperior parietal lobule, superior temporal gyrus   Braak stage at I to VI      Affymetrix Human Genome U133A ArrayAffymetrix Human Genome U133B ArrayAffymetrix Human Genome U133 Plus 2.0 Array   1,146               64
                   GSE93885      Olfactory bulb                                                                                                                                                                                                                                                                                                                                                                                  --                          Affymetrix Human Gene 2.0 ST Array \[transcript (gene) version\]                                                    18                  0
  RNA-Seq          GSE104704     Lateral temporal lobe                                                                                                                                                                                                                                                                                                                                                                           Braak stage at V to VI      Illumina HiSeq 2500 (Homo sapiens)                                                                                  30                  --
                   GSE95587      Fusiform gyrus                                                                                                                                                                                                                                                                                                                                                                                  Braak stage at III to VI    Illumina HiSeq 2500 (Homo sapiens)                                                                                  117                 --
                   GSE53697      Dorsolateral prefrontal cortex                                                                                                                                                                                                                                                                                                                                                                  Braak stage at II to VI     Illumina HiSeq 2500 (Homo sapiens)                                                                                  17                  --
                   GSE67333      Hippocampus                                                                                                                                                                                                                                                                                                                                                                                     Braak stage at V to VI      Illumina HiSeq 2000 (Homo sapiens)                                                                                  8                   --

![The flow diagram of datasets selection, including identification, screening, eligibility and inclusion stage.](fnins-14-00209-g002){#F2}

Preprocessing of Datasets and Determination of Differentially Expressed Genes {#S3.SS2}
-----------------------------------------------------------------------------

After the selection process of the datasets, all included datasets contained complete transcriptomic raw data, and were undergone a quality control as a prioritization procedure. In the included microarray datasets, the quality of the normalized dataset was assessed using the R package *arrayQualityMetrics*. Different numbers of arrays were identified as outliers and omitted in the subsequent analysis ([Table 2](#T2){ref-type="table"}). In the included RNA-Seq datasets, the reads were mapped to the *Homo.sapiens* reference genome (GRCh38.94) after sequence quality assessment. The mapping rates were above 95% for the RNA-Seq datasets. From the mapped reads, the genes were counted to determine DEGs. After preprocessing steps, different numbers of DEGs were determined from each comparison, ranging from 0 to over 10,000 ([Table 3](#T3){ref-type="table"}). There were 21,064 DEGs in all comparisons that compared AD brain samples with healthy brain samples, and 16,810 DEGs (79.76%) were reported in at least two comparisons ([Supplementary File S2](#SF2){ref-type="supplementary-material"}). In the meta-analysis of DEGs, 9,298 DEGs were found to be statistically significant ([Supplementary File S3](#SF3){ref-type="supplementary-material"}); 4,960 genes were downregulated and 4,338 genes were upregulated. The most reported downregulated DEGs were *DPP6* and *FXYD7*, which were reported in 16 comparisons; *RHOQ* was the most reported upregulated DEG among all 15 reported comparisons. A loss of *DPP6* or *FXYD7* is reported to dysregulate neuronal excitation ([@B61]; [@B21]), while *RHOQ* is reported to enhance Aβ oligomerization ([@B1]). Multiple DEGs involved in Aβ clearance were found statistically significant in meta-analysis ([Table 4](#T4){ref-type="table"}). These DEGs could be categorized into UPS, autophagy, and UPR, implying the downregulated Aβ clearance. The statistically significant DEGs in UPS and autophagy were mostly downregulated, while those in UPR were mostly upregulated, proposing a dysfunctional homeostasis. The impaired Aβ clearance resulting from dysfunctional homeostasis is suggested to induce Aβ accumulation in sporadic AD, in contrast with the overproduction of Aβ in familial AD ([@B93]; [@B120]).

###### 

The number of DEGs determined from each comparison.

  Comparison_ID                                No of   No of   No of
  -------------------------------------------- ------- ------- --------
  E-MEXP-2280                                  5       7       0
  GSE32645                                     3       3       0
  GSE110226                                    5       5       475
  GSE61196_CvsBraak3                           7       7       1,597
  GSE61196_CvsBraak6                           7       6       1,723
  GSE33000                                     154     283     12,742
  GSE12685                                     6       5       2
  GSE1297_CvsIni                               8       6       0
  GSE1297_CvsMod                               9       8       0
  GSE1297_CvsSev                               9       6       7
  GSE93885_CvsIni                              4       5       0
  GSE93885_CvsMod                              4       4       0
  GSE93885_CvsSev                              4       5       0
  GSE29378_CA1                                 16      15      2
  GSE29378_CA3                                 16      14      1
  GSE26927                                     4       10      0
  GSE16759                                     3       4       0
  GSE37263                                     8       7       0
  GSE48350_EC                                  36      14      7,185
  GSE48350_HIP                                 43      18      3,958
  GSE48350_PCG                                 39      22      1,540
  GSE48350_SFG                                 46      19      6,148
  GSE28146_CvsIni                              8       7       0
  GSE28146_CvsMod                              8       8       0
  GSE28146_CvsSev                              8       6       0
  GSE5281_EC                                   12      9       9,921
  GSE5281_HIP                                  13      10      7,176
  GSE5281_MTG                                  11      16      9,981
  GSE5281_PC                                   12      8       8,978
  GSE5281_PVC                                  12      16      38
  GSE5281_SFG                                  22      9       5,054
  GSE44768                                     98      122     1,447
  GSE44770                                     81      121     1,778
  GSE44771                                     89      119     4,732
  GSE84422_Amygdala                            14      16      1,253
  GSE84422_Nucleus_accumbens                   12      16      9
  GSE84422_96_Anterior_cingulate               16      20      0
  GSE84422_96_Caudate_nucleus                  11      18      0
  GSE84422_96_Dorsolateral_prefrontal_cortex   15      15      0
  GSE84422_96_Frontal_pole                     14      21      0
  GSE84422_96_Hippocampus                      10      18      0
  GSE84422_96_Inferior_frontal_gyrus           11      17      0
  GSE84422_96_Inferior_temporal_gyrus          13      18      0
  GSE84422_96_Middle_temporal_gyrus            14      19      0
  GSE84422_96_Occipital_visual_cortex          11      13      0
  GSE84422_96_Parahippocampal_gyrus            14      21      0
  GSE84422_96_Posterior_cingulate_cortex       12      23      0
  GSE84422_96_Precentral_gyrus                 5       18      0
  GSE84422_96_Prefrontal_cortex                11      18      35
  GSE84422_96_Putamen                          9       17      0
  GSE84422_96_Superior_parietal_lobule         13      12      0
  GSE84422_96_Superior_temporal_gyrus          14      20      0
  GSE84422_96_Temporal_pole                    14      18      0
  GSE84422_97_Anterior_cingulate               14      19      0
  GSE84422_97_Caudate_nucleus                  9       16      0
  GSE84422_97_Dorsolateral_prefrontal_cortex   16      14      1
  GSE84422_97_Frontal_pole                     15      22      0
  GSE84422_97_Hippocampus                      10      18      0
  GSE84422_97_Inferior_frontal_gyrus           11      17      0
  GSE84422_97_Inferior_temporal_gyrus          13      18      30
  GSE84422_97_Middle_temporal_gyrus            13      20      0
  GSE84422_97_Occipital_visual_cortex          12      13      0
  GSE84422_97_Parahippocampal_gyrus            14      22      0
  GSE84422_97_Posterior_cingulate_cortex       12      22      0
  GSE84422_97_Precentral_gyrus                 5       17      0
  GSE84422_97_Prefrontal_cortex                11      19      0
  GSE84422_97_Putamen                          9       18      0
  GSE84422_97_Superior_parietal_lobule         13      13      0
  GSE84422_97_Superior_temporal_gyrus          14      20      1
  GSE84422_97_Temporal_pole                    14      18      0
  GSE36980_FC                                  17      13      0
  GSE36980_HIP                                 10      5       587
  GSE36980_TC                                  17      9       5
  GSE104704_Old                                10      12      1,070
  GSE95587                                     33      84      6,611
  GSE53697                                     8       9       1
  GSE67333                                     4       4       10

###### 

The dysregulated status of genes involved in ubiquitin-proteasome system, autophagy, and unfolded-protein response for Aβ clearance.

  Functional category   Genes       Adjusted *P*-value   Dysregulated state
  --------------------- ----------- -------------------- --------------------
  Ubiquitin             *PRKN*      1.77E-06             Downregulated
  -proteasome           *UCHL1*     2.70E-02             Downregulated
  system (UPS)          *UCHL3*     1.47E-20             Downregulated
                        *PSMC1*     2.09E-24             Downregulated
                        *UBE2D2*    2.02E-24             Downregulated
                        *STUB1*     1.62E-18             Downregulated
                        *NEDD8*     1.88E-31             Downregulated
                        *ATXN1*     0.61                 Downregulated
                        *ATXN3*     0.79                 Upregulated
                        *ATXN7*     0.97                 Upregulated
  Autophagy             *BECN1*     1.42E-20             Downregulated
                        *MTOR*      1.16E-15             Downregulated
                        *TFEB*      2.06E-36             Upregulated
                        *ATG5*      5.20E-19             Downregulated
                        *ATG7*      1.78E-32             Downregulated
                        *TREM2*     5.06E-32             Upregulated
                        *MS4A4A*    8.77E-22             Upregulated
                        *PLCG2*     6.91E-26             Upregulated
                        *ABI3*      1.83E-19             Upregulated
                        *ATG12*     0.94                 Downregulated
                        *PICALM*    0.86                 Upregulated
                        *SQSTM1*    0.20                 Upregulated
  Unfolded              *ERN1*      1.05E-13             Upregulated
  -protein              *EIF2AK3*   2.00E-10             Upregulated
  response (UPR)        *TMEM259*   6.57E-11             Downregulated
                        *XBP1*      2.95E-14             Upregulated

However, several genes involved in Aβ clearance were not found statistically significant in meta-analysis, although they were reported as DEGs in separated comparisons. The heat shock proteins work coordinately with UPS for protein clearance, remodeling the misfolded proteins before the degradation by UPS. Both systems are upregulated to restore dysfunctional homeostasis at the beginning ([@B68]). However, the genes for most heat shock proteins, such as *ATXN1*, *ATXN3*, and *ATXN7*, were not statistically significant ([Supplementary File S3](#SF3){ref-type="supplementary-material"}), suggesting that the early event of AD might not be truly reflected. *PICALM* and *SQSTM1* which are involved in autophagosome formation ([@B98]; [@B109]), were not reported as DEGs in the meta-analysis. Several autophagic marker genes, *MAP1LC3B* and *ATG12*, associated with autophagosomal function ([@B87]), were also found as a statistically insignificant in the meta-analysis. The expression of *TREM2* was upregulated, which was contradictory to the role of *TREM2* reported in autophagy ([@B86]), but consistent with that reported in Aβ plaque-activated microglia ([@B172]; [@B170]). Meanwhile, those genes involved in Aβ plaque-activated microglia, *MS4A4A*, *PLCG2*, and *ABI3*, were also found significantly upregulated in the meta-analysis.

On the enrichment analysis, AD itself was identified as significant ([Figure 3A](#F3){ref-type="fig"}). In the AD pathway, components related to the mitochondrial respiratory chain were downregulated, while components related to Ca^2+^ channels that transport Ca^2+^ from the ER into the cytoplasm were upregulated ([Figure 3B](#F3){ref-type="fig"}). Several AD-related pathways, including proteasome, oxidative phosphorylation, and retrograde endocannabinoid signaling pathways, were also identified as statistically significant; most components in these pathways were downregulated ([Figures 3C--E](#F3){ref-type="fig"}). Downregulation of the proteasome decreases the clearance of Aβ ([@B59]), while downregulation of oxidative phosphorylation decreases the efficacy of the mitochondrial respiratory chain, suggesting hypometabolism in the AD brain ([@B100]). The genes (e.g., *MFN1*, *OPA1*, and *DNM1L*) involved in mitochondrial fusion and fission were downregulated ([@B159]), disturbing mitochondrial biogenesis to adopt energetic demands. The aberrant mitochondria were removed by the process, mitophagy. However, the genes responsible for mitophagy, *PINK1* and *PRKN* ([@B102]), were downregulated, which further increased the burden of damaged protein clearance. The regulation of genes involved in oxidative phosphorylation in mitochondria was severely impaired in the present study, including genes for NADH dehydrogenase, succinate dehydrogenase, cytochrome *c* reductase, and cytochrome *c* oxidase in the electron transport chain. eCBs are signaling molecules used among nearby cells over short distances, and they modulate neuronal transmission. There is a high density of cannabinoid receptors in presynaptic terminals in the hippocampus and limbic cortex, indicating a role for cannabinoids in cognitive information processing ([@B177]). A disruption of eCB signaling has been reported in AD, which influences neurotransmitter release ([@B10]). In the current study, most members of the retrograde endocannabinoid signaling pathway were downregulated, interfering with the role of eCBs in the release of glutamate and GABA in synapses.

![The AD-related biological pathways as impacted in health vs. AD subjects, **(A)** the top 10 statistically significant pathways from enrichment analysis result; **(B)** Alzheimer's disease; **(C)** Proteasome; **(D)** Oxidative phosphorylation; and **(E)** Retrograde endocannabinoid signaling. For figure 3B-E, the red and green represent upregulation and downregulation, respectively.](fnins-14-00209-g003){#F3}

Subgroup Analysis {#S3.SS3}
-----------------

Among 77 comparisons, 15 investigated the amygdala and hippocampus of AD subjects, while 28 focused on the cerebral cortex ([Table 5](#T5){ref-type="table"}). Statistically significant DEGs for each subgroup analysis are shown in [Supplementary File S4](#SF4){ref-type="supplementary-material"}. There were 2,260 DEGs that were reported as significant in the amygdala and hippocampus, while 6,636 DEGs were reported as significant in the cerebral cortex. Among the 1,390 commonly found DEGs, 359 upregulated and 1,020 downregulated DEGs were consistently found in two subgroups. Eleven DEGs were upregulated in one subgroup but downregulated in another subgroup. The most highly upregulated and downregulated DEGs were *S100A6* and *STMN4*, respectively, in both subgroups. The protein calcyclin (encoded by *S100A6*) is a calcium-binding protein that is highly expressed in astrocytes surrounding Aβ deposits, and is involved in neuronal death via zinc depletion ([@B9]). The protein stathmin (encoded by *STMN4*) binds tubulin to mediate microtubule dynamics, and dysregulation of stathmin-mediated microtubule stability induces memory loss ([@B149]).

###### 

The datasets used in the subgroup analysis.

  Subgroups                       No of control   No of disease   No of DEGs   No of pathways   Comparison_ID
  ------------------------------- --------------- --------------- ------------ ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cerebellum                      98              122             --           --               GSE44768
  Putamen and nucleus accumbens   30              51              --           --               GSE84422_96_Putamen, GSE84422_97_Putamen, GSE84422_Nucleus_accumbens
  Amygdala and hippocampus        175             159             2,260        18               GSE84422_Amygdala, GSE1297_CvsIni, GSE1297_CvsMod, GSE1297_CvsSev, GSE28146_CvsIni, GSE28146_CvsMod, GSE28146_CvsSev, GSE29378_CA1, GSE29378_CA3, GSE36980_HIP, GSE48350_HIP, GSE5281_HIP, GSE84422_96_Hippocampus, GSE84422_97_Hippocampus, GSE67333
  Cerebral neocortices            632             849             6,636        25               E-MEXP-2280, GSE12685, GSE16759, GSE26927, GSE32645, GSE33000, GSE36980_FC, GSE36980_TC, GSE37263, GSE44770, GSE44771, GSE48350_EC, GSE5281_EC, GSE5281_PVC, GSE84422_96_Dorsolateral_prefrontal_cortex, GSE84422_96_Frontal_pole, GSE84422_96_Occipital_visual_cortex, GSE84422_96_Prefrontal_cortex, GSE84422_96_Superior_parietal_lobule, GSE84422_96_Temporal_pole, GSE84422_97_Dorsolateral_prefrontal_cortex, GSE84422_97_Frontal_pole, GSE84422_97_Occipital_visual_cortex, GSE84422_97_Prefrontal_cortex, GSE84422_97_Superior_parietal_lobule, GSE84422_97_Temporal_pole, GSE104704_Old, GSE53697

In the subgroup enrichment analyses, the pathways for proteasome and retrograde endocannabinoid signaling were found in both subgroups ([Figures 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}). For the subgroup of the amygdala and hippocampus, the synaptic vesicle cycle was identified as statistically significant, and most components in this pathway were downregulated ([Figure 4F](#F4){ref-type="fig"}). Downregulated synaptic functions decrease the release of neurotransmitters from neurons, inducing memory-related symptoms in AD. For the subgroup of the cerebral cortex, several synaptic signaling pathways were identified in AD, including the MAPK signaling pathway, dopaminergic synapses, and the insulin signaling pathway; the components in these pathways were mostly downregulated ([Figures 5D--F](#F5){ref-type="fig"}). The role of the MAPK effector, JNK, is to dissociate Beclin 1 from Bcl-2 to mediate autophagy, and downregulation of JNK reduces autophagy ability ([@B176]). The loss of dopaminergic synapses in the ventral tegmental area reduces the release of dopamine toward the cortex and hippocampus, and is reported to be associated with memory loss in AD before the formation of amyloid plaques ([@B107]). Although all AD datasets collected in this study did not report suffering from T2DM, the dysfunctional insulin signaling was identified, suggesting an effect of Aβ in insulin signaling pathway. Aβ shares a common sequence with insulin, antagonizing the regulatory effects of insulin ([@B43]). In the canonical insulin signaling pathway, insulin binds receptors to activate Akt for mediating downstream effects, e.g., translocating glucose receptors to cellular membrane, activating mTOR for autophagy regulation, and inhibiting GSK3β for tau protein phosphorylation. Losing the regulatory effects of insulin may induce dysfunctional autophagy and tau protein hyperphosphorylation, potentiating AD development. The increased level of free insulin due to Aβ blockage reduces Aβ clearance via IDE, because insulin has a higher affinity to IDE than Aβ ([@B41]). On the other hand, the AD progression reduces the transport of insulin across BBB, decreasing insulin signaling in brain ([@B140]).

![The AD-related biological pathways from the subgroup amydala and hippocampus, **(A)** the top 10 statistically significant pathways from enrichment analysis result; **(B)** Alzheimer's disease; **(C)** Proteasome; **(D)** Oxidative phosphorylation; **(E)** Retrograde endocannabinoid signaling; and **(F)** Synaptic vesicle cycle. The red and green represent upregulation and downregulation, respectively.](fnins-14-00209-g004){#F4}

![The AD-related biological pathways from the subgroup cerebral cortex, **(A)** the top 10 statistically significant pathways from enrichment analysis result; **(B)** Proteasome; **(C)** Retrograde endocannabinoid signaling; **(D)** MAPK signaling pathway; **(E)** Dopaminergic synapse; and **(F)** Insulin signaling pathways. The red and green represent upregulation and downregulation, respectively.](fnins-14-00209-g005){#F5}

In the present study, several datasets focused on the hippocampus and entorhinal cortex because these two regions suffer the most significant neuronal loss in the early stage of AD, while no significant neuronal loss is observed in these regions during normal aging. The transcriptome from these brain regions therefore represents the chronic response to the causes and consequences, or the treatment, of AD.

Quality Assessment of Studies {#S3.SS4}
-----------------------------

MIAME and MINSEQE guidelines were used to assess the transcriptomic analysis of studies ([@B14], [@B13]; [@B85]; [@B12]; [@B19]; [@B161]; [@B110]; [@B146]; [@B37]; [@B5]; [@B42]; [@B65]; [@B95]; [@B173]; [@B57]; [@B101]; [@B88]; [@B132]; [@B155]; [@B78]; [@B45]; [@B103]; [@B141]) that published the datasets that were used in the present study. The results of quality assessments are shown in [Figure 6](#F6){ref-type="fig"}. Among the 19 studies that published the microarray datasets, 80% did not provide the brain sample size or the weight used for RNA extraction for sample annotation and experimental variables, and only two studies provided sufficient information about experimental design, including quality control of samples. Furthermore, the annotations of array designs, including microarray quality indicators, were not fully reported for most studies (95%). For 40% of the studies, experimental and data processing details, including normalization methods and cut-offs for DEGs, were not fully reported. Among the four studies that published the RNA-Seq datasets, no study provided the brain sample size or the weight used for RNA extraction, or the details of experimental parameters used for RNA-Seq procedures. Furthermore, half of the studies did not provide sufficient information about experimental and data processing protocols, including the cut-offs for DEGs.

![The overall quality assessment for **(A)** 19 studies for DNA microarray and **(B)** 4 studies for RNA-seq. Green color represents low risk of bias, which the authors clearly provided the information with full detail. Yellow color represents unclear risk of bias, which the authors provided the information without full detail. Red color represents high risk of bias, which the authors did not provide the correct information.](fnins-14-00209-g006){#F6}

The relatively low quality of the studies indicates the insufficient information related to transcriptomic analysis provided in the studies, raising the reproducibility issue. Also, the transcriptomic results might be influenced, blurring some pathological events in the postmortem AD brains. The genes encoded heat shock proteins (e.g., *ATXN1*, *ATXN3*, and *ATXN7*) were not found statistically significant in the meta-analysis, while the multiple genes involved in neuroinflammation (e.g., *CXCL3*, *IFNG*, *IL6*, *IL13*, and *CXCL9*) ([@B47]) were only reported as DEGs in one dataset, and therefore were not collected for meta-analysis. Although both heat shock proteins recruitment and neuroinflammation are associated with AD development, their pathological roles in AD development might not fully reflected in this study.

Construction of a Protein--Protein Interaction Network to Identify Potential Pathogenic Factors {#S3.SS5}
-----------------------------------------------------------------------------------------------

The DEGs from the meta-analysis were used to retrieve the corresponding proteins in interactions according to STRING. The PPIN consisted of 4,781 nodes (2,083 upregulated nodes and 2,698 downregulated nodes) and 51,076 edges ([Figure 7A](#F7){ref-type="fig"}) and there were 105 AD seed genes ([Supplementary File S5](#SF5){ref-type="supplementary-material"}) retrieved from the GWAS Catalog. The PPIN exhibited scale free topology with the degree distribution following a power law distribution (*y* = 3779.2x^--1^.^481^) and the most proteins were closely linked. In the PPIN, polyubiquitin-C (endcoded by *UBC*) and E3 ubiquitin-protein ligase RBX1 (encoded by *RBX1*), were the two proteins with the highest degree (372 and 222, respectively). These proteins were downregulated and are parts of UPS for protein degradation. The dysfunctional proteasome is regarded as an early event of AD ([@B89]), e.g., the decreased proteasomal clearance enhances mitochondrial dysfunction ([@B15]).

![**(A)** The PPIN constructed from DEGs and the PPIN topology parameters. The red and green represent upregulation and downregulation, respectively. **(B)** A disease module, derived from the DIAMOnD algorithm, consisting of AD seed proteins (represented as squares) and their corresponding DIAMOnD proteins (represented as circles). The colors of the nodes represent upregulation (red), and downregulation (green). The edges represent seed-seed interaction (dark green), seed-DIAMOnD interaction (purple), and DIAMOnD-DIAMOnD interaction (pink).](fnins-14-00209-g007){#F7}

The PPIN for each protein pair was extracted for the subsequent DIAMOnD algorithm with AD seed genes to obtain a disease module. Not every seed gene was biologically linked to AD; some were involved in AD comorbidity disease. Among the disease modules ([Figure 7B](#F7){ref-type="fig"}), the two nodes with a high degree (\>95th percentile) were selected as potential pathogenic factors, and included EGFR and Fyn. The EGFR was the Aβ oligomer receptor, in which Aβ oligomer is regarded as the causative toxic species. The hydrophobic residues of Aβ oligomers are more easily accessible and interacting with cellular proteins, compared with Aβ fibrils ([@B160]). Fyn is involved in Aβ signal transduction and tau protein phosphorylation, and is changed in synaptic signaling pathways, including MAPK signaling pathway. These two proteins are both Aβ-relevant receptors, mediating the Aβ oligomers downstream neurotoxicity.

Discussion {#S4}
==========

We used a meta-analysis approach based on DNA microarray and RNA-Seq datasets from multiple brain regions to reveal potential pathogenic factors of AD. Perturbations in the genes involved in the proteasome, oxidative phosphorylation, and retrograde endocannabinoid signaling pathways were identified. The proteasome is required to degrade the damaged proteins to maintain the cellular functionality. The decreased proteasome activity results in an accumulation of ubiquitinated and damaged proteins ([@B35]). The ubiquitination degradation of APP by the proteasome includes several key genes, such as *PRKN*, *NEDD8*, *PSMC1*, *UCHL1*, and *UCHL3* ([@B11]; [@B29]; [@B174]; [@B108]). Tau-specific ubiquitin--proteasome related genes, including *UBE2D2* ([@B137]) and *STUB1* ([@B130]), were also downregulated. The downregulation of these genes might result in impaired Aβ and phosphorylated tau protein clearance ([Table 4](#T4){ref-type="table"}). The oligomeric Aβ itself disrupts the catalytic activity of proteasome ([@B148]), forming a positive feedback loop to worsen the Aβ clearance by proteasome. The disrupted catalytic activity of proteasome may also lose its inhibition of presenilin complex, which is the catalytic complex for γ-secretase, enhancing Aβ production ([@B25]). The accumulated Aβ, located on the mitochondria, deleteriously impairs oxidative phosphorylation, decreasing ATP production in the mitochondria ([@B28]; [@B99]). The ATP-dependent proteins (i.e., the Ca^2+^ pumps located on the endoplasmic reticulum (ER) and ATP-dependent ion pumps) are unable to maintain their physiological functions, interfering neurotransmitter release and memory formation ([@B143]). The ATP-dependent molecular chaperones are also failed to work coordinately with UPS to remodel the misfolded proteins ([@B92]).

The reduced activity of proteasome enhances the burden of Aβ clearance on the autophagy and UPR. Autophagy is the process of degrading redundant cellular components by delivering them to lysosomes and forming autophagosomes. Beclin 1 (encoded by *BECN1*) is an essential component of autophagososomal structure ([@B64]), but its autophagy function is inhibited by interacting with Bcl-2 (encoded by *BCL2*) leading to cellular death ([@B91]). The downregulation of *BECN1* and upregulation of *BCL2* in the present study indicated autophagic flux failure. Autophagy is inhibited by the upregulation of *mTOR* and activated by the downregulation of *TFEB* ([@B22]; [@B119]). The downregulation of *mTOR* and upregulation of *TFEB* in the present study induced the formation of immature autophagosomes, impairing Aβ clearance. In addition, the downregulation of *mTOR* is associated with AD development ([@B44]), memory impairment ([@B138]), and neuronal apoptosis ([@B169]). The depletion of autophagy-related genes, including *Atg5* and *Atg17*, impairs the elongation of phagopores to form autophagosomes, resulting in Aβ accumulation ([@B52]; [@B106]). Accumulated Aβ on the ER membrane induces ER stress, which is relieved by the activation of UPR. The activation of UPR is induced by the accumulation of misfolded proteins ([@B142]), and has been reported in AD subjects ([@B133]). Two main UPR proteins, including PERK (encoded by *EIF2AK3*) and IRE-1 (encoded by *ERN1*), were upregulated and activated in AD due to misfolded Aβ oligomers ([@B66]), although a recent critical review suggested that the involvement of ER stress in AD might be exaggerated by the misuse of APP/PS1-overexpressing AD mouse models ([@B55]). The activation of UPR is a significant approach to prevent the accumulation of misfolded proteins, but may also increase Aβ production ([@B133]), and result in synaptic loss ([@B50]). Taken together, disturbed Aβ clearance could be the upstream event for AD pathological development, to induce Aβ accumulation, altering intracellular ionic gradients and resulting in insufficient oxidative phosphorylation.

The two top pathogenic factors determined in the present study, Fyn and EGFR, are key receptors in Aβ downstream signaling. Fyn is a protein tyrosine kinase belonging to the Src family, and it mediates synaptic plasticity in the central nervous system ([@B70]). The soluble Aβ oligomer binds to PrP^*C*^ with high affinity ([@B79]), and interrupts the PrP^*C*^'s autoinhibitory mechanism ([@B163]), overactivating Fyn to increase glutamate release ([@B147]). Overactivation of Fyn, however, alters NMDA receptor function and intracellular Ca^2+^ homeostasis, rendering neurons vulnerable to Aβ-induced neurotoxicity. The Aβ-activated Fyn can phosphorylate downstream tau proteins at Tyr18 ([@B80]), and tau proteins participate in transporting Fyn to post-synaptic densities around glutamate receptors ([@B63]). Fyn is a key protein that links between extracellular Aβ and intracellular tau protein, and unites these two pathologies in AD. The activity of Fyn is gene-dose-dependent ([@B150]); that is, downregulation of *FYN* reduces Aβ-induced neurotoxicity, while upregulation of *FYN* exacerbates Aβ-induced neurotoxicity. In previous studies, overexpression of *FYN* has also been reported to accelerate synaptic loss, making Fyn inhibition a potential therapeutic treatment for AD ([@B32]; [@B31]). Saracatinib (AZD0530) is a Src kinase inhibitor that is being tested clinically for the treatment of AD. Saracatinib blocks Fyn activation to rescue memory deficits, and exhibits well-tolerated effects in mild-to-moderate AD subjects ([@B111]). A recently published clinical trial ([@B151]) revealed that saracatinib does not slow the decline in the CMRgl, and does not exhibit beneficial effects on several cognitive assessments, compared with the placebo group. However, a trend for slowing the reduction of volumetric measure in brain is observed, and a *post hoc* exploratory analysis deduces a statistically significant decline in CMRgl in the entorhinal cortex. Although the frequent adverse event of saracatinib, e.g., diarrhea, may limit the feasibility of increasing 125 mg daily to a higher dosage, the authors proposed that a higher dosage of saracatinib may be beneficial to slow decline of CMRgl in AD participants, who have greater tolerability.

EGFR is more commonly associated with cancer than with AD. However, the expression of EGFR is statistically correlated with the expression of γ-secretase, suggesting a significant role of EGFR in AD ([@B175]). EGFR is widely distributed in the hippocampus and cerebral cortex ([@B46]), and EGFR signaling exerts neurotrophic functions to regulate synaptic architecture in the central nervous system ([@B113]). The expression of *EGFR* is reported to be upregulated in the brains of AD animals, and overactivation of EGFR by Aβ oligomers induces memory loss ([@B154]). The overactivation of EGFR can also be induced by the prolong UPR ([@B117]). The levels of overactivated EGFR can be suppressed by treatment with the EGFR inhibitor gefitnib to rescue memory loss. Activation of EGFR also induces downstream neuroinflammatory cascades in response to Aβ-induced neurotoxicity. Afatinib, an orally available EGFR tyrosine kinase inhibitor, inhibits EGFR activation to alleviate neuroinflammation by reducing caspase 1 activation and interleukin-1β levels in neurodegenerative diseases ([@B30]). Antagonizing Aβ-induced activation of EGFR may have beneficial effects to slow memory loss and alleviate neuroinflammation. [Figure 8](#F8){ref-type="fig"} summarizes the mechanism of action of Aβ-mediated Fyn and EGFR in AD, as described above.

![The mechanism of action of Aβ-mediated Fyn and EGFR in AD.](fnins-14-00209-g008){#F8}

Besides the genes involved in Aβ downstream neurotoxicity, the genes related to amyloid clearance proteins (e.g., *ECE1* and *NEU1*) are reported as pathogenic factors of AD by other studies. Endothelin 1 (encoded by *ECE1*) is implicated in Aβ degradation and downregulation of *ECE1* enhances Aβ deposition ([@B114]). However, upregulation of *ECE1* was found in the present study, suggesting that the pathophysiological role of *ECE1* was not solely involved in Aβ metabolism, but also associated with the increase Aβ-induced vasoconstriction in AD ([@B115]). Sialidase (encoded by *NEU1*) is a lysosomal enzyme for Aβ clearance through lysosomal exocytosis ([@B4]). Deficit of *NEU1* causes Aβ-induced proteasome inhibition, which was consistent with our results. Disruption of Aβ clearance proteins may be the secondary events of AD progression, rather than the primary cause. Increasing evidences show a correlation between T2DM and higher risk of developing AD, through increasing BBB permeability by chronic peripheral inflammation ([@B58]). The BBB leakage was supported by the dysregulated genes in this study, including *OCLN*, *TJP1*, *CDH5*, and *CTNNB1*, which encode the tight junction proteins. The compromised BBB can be exacerbated by chronic hypertension ([@B131]) and microbial pathogens ([@B83]), and alters peripheral immune cell trafficking to the brain and induces neuroinflammation. The neuroinflammation is mediated by p38 (encoded by *MAPK14*), which is a protein found in MAPK pathway. p38 is also a kinase to phosphorylate tau protein, making p38 as a potential pathogenic factor of AD. However, upregulation of p38 was not observed in this study, since p38 participates in numerous cellular events not only neuroinflammation. This can be supported by that although the inhibition of p38 alleviates neuroinflammation in AD ([@B168]; [@B6]), most p38 inhibitors are failed in clinical trials due to off-target effects. A gene converting glucose into lactate in glycolysis, *LDHA*, is regarded as a relevant pathogenic factor in AD, although it may not be specific to AD pathogenesis. Overexpression of *LDHA* is reported to prevent neurons from Aβ neurotoxicity by shifting mitochondrial glucose metabolism to lactate production, and decreasing ROS production ([@B105]). However, elevated lactate level may be detrimental to neurons ([@B54]). Although the expression of *LDHA* was insignificantly downregulated in this study, the opposing neuroprotective and neurotoxic effects of *LDHA* suggested that neurons might have its own defense mechanism against Aβ in the early onset of AD.

The strength of this study is the integration of transcriptomic data from both DNA microarrays and RNA-Seq using a systematic search and consistent workflow. However, there are some limitations. First, the articles that published the datasets did not provide full details of the experimental procedures, making the transcriptomic results less reliable and more difficult to repeat. In addition, the transcriptomic data retrieved from postmortem brain tissue using different methods might be biased. For example, laser-microdissection mainly targets neuronal soma, but may miss transcripts transporting to the pre- or post-synapses. Lacking of sufficient information about disposal of transcriptomic analysis, resulting in relatively low quality of the selected studies, might raise a reproducibility issue. Second, the confounding factors of postmortem brain tissues include age, sex, and postmortem interval, and may blur the results, e.g., neuroinflammation. Third, most included datasets in this study focused on hippocampus and entorhinal cortex, in which the brain region AD are believed to start. However, AD might start differently from those two brain regions, e.g., the impaired UPS as an early AD event was reported in brainstem ([@B62]). Transcriptomic analysis in different regions of postmortem AD brains would provide more novel insights of AD development.

Conclusion {#S5}
==========

This meta-analytical study suggested that the reduced Aβ clearance in AD pathogenesis was associated with the genes encoding Fyn and EGFR, which were key receptors in Aβ downstream signaling.
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Aβ
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AD

:   Alzheimer's disease

BBB

:   blood-brain barrier
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:   cerebral metabolic rate for glucose
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:   differentially expressed genes
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:   false discovery rate
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:   insulin-degrading enzyme
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:   Kyoto Encyclopedia of Genes and Genomes
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:   protein--protein interaction network
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:   type 2 diabetes mellitus
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:   unfolded-protein response
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:   ubiquitin-proteasome system.

[^1]: Edited by: Woon-Man Kung, Chinese Culture University, Taiwan

[^2]: Reviewed by: Chung-Feng Kao, National Chung Hsing University, Taiwan; Judith Potashkin, Rosalind Franklin University of Medicine and Science, United States

[^3]: This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
